Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC

Dr Marina Garassino - National Tumor Institute, Milan, Italy

Comment: Nivolumab plus ipilimumab combination for advanced NSCLC ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer...

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

PARP inhibitor olaparib added to bevacizumab benefits women with ovarian cancer with and without a BRCA mutation ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: Osimertinib for EGFR-mutation positive NSCLC

Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain

Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )

Nivolumab plus ipilimumab combination offers chemotherapy-free option for...

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )

Front-line osimertinib significantly lengthens overall survival in EGFR...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

More ovarian cancer patients benefit from maintenance combined targeted therapy

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Comment: Front-line osimertinib significantly lengthens overall survival in...

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre...

Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Adding daratumumab to existing multiple myeloma regimen of lenalidomide...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

More from ecancer